Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Praneeth Reddy Sudalagunta, PhD, applied research scientist, Moffitt Cancer Center, Tampa, Florida, discusses the differential effects of bridging therapy on the immune microenvironment as well as outcomes with…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Hidradenitis suppurativa (HS) often poses a therapeutic challenge to physicians treating the condition. Severe cases can be refractory to a multitude of therapies, both surgical and medicinal alike.…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Spinal muscular atrophy (SMA) is the result of being born without – or with a defective version of – the survival motor neuron 1 (SMN1) gene. This gene…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
TXA-709 is a new type of antibiotic being developed by TAXIS Pharmaceuticals. The antibiotic specifically targets variants of the MRSA bacteria. TXA-709, a FtsZ-targeting benzamide prodrug, should be…
Researchers from the British Columbia Cancer Agency and UBC Vancouver Coastal Health have found a protein present in the malaria parasite that easily bonds with a sugar molecule…
